Publicaciones en colaboración con investigadores/as de Institute Catalá Oncología (16)

2024

  1. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

    Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

2022

  1. Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer

    Journal for immunotherapy of cancer, Vol. 10, Núm. 12

2021

  1. Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer

    Molecular Oncology, Vol. 15, Núm. 2, pp. 350-363

  2. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era

    European urology oncology, Vol. 4, Núm. 3, pp. 502-505

2020

  1. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

    Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282

2019

  1. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens

    Cancer Cytopathology, Vol. 127, Núm. 5, pp. 285-296

2018

  1. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781

2017

  1. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens

    Cancer Cytopathology, Vol. 125, Núm. 8, pp. 615-626

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. A novel epigenetic signature for early diagnosis in lung cancer

    Clinical Cancer Research, Vol. 22, Núm. 13, pp. 3361-3371

2015

  1. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

  2. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer

    PLoS ONE, Vol. 10, Núm. 3

2014

  1. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633

2013

  1. A prognostic DNA methylation signature for stage I non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 31, Núm. 32, pp. 4140-4147

2010

  1. Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer

    Cancer Epidemiology Biomarkers and Prevention, Vol. 19, Núm. 10, pp. 2665-2672

2008

  1. A microRNA DNA methylation signature for human cancer metastasis

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, Núm. 36, pp. 13556-13561